Literature DB >> 26036877

Incidence of Surgical Site Infection Following Mastectomy With and Without Immediate Reconstruction Using Private Insurer Claims Data.

Margaret A Olsen1, Katelin B Nickel1, Ida K Fox2, Julie A Margenthaler3, Kelly E Ball1, Daniel Mines4, Anna E Wallace4, Victoria J Fraser1.   

Abstract

OBJECTIVE: The National Healthcare Safety Network classifies breast operations as clean procedures with an expected 1%-2% surgical site infection (SSI) incidence. We assessed differences in SSI incidence following mastectomy with and without immediate reconstruction in a large, geographically diverse population.
DESIGN: Retrospective cohort study. PATIENTS: Commercially insured women aged 18-64 years with ICD-9-CM procedure or CPT-4 codes for mastectomy from January 1, 2004 through December 31, 2011
METHODS: Incident SSIs within 180 days after surgery were identified by ICD-9-CM diagnosis codes. The incidences of SSI after mastectomy with and without immediate reconstruction were compared using the χ2 test.
RESULTS: From 2004 to 2011, 18,696 mastectomy procedures among 18,085 women were identified, with immediate reconstruction in 10,836 procedures (58%). The incidence of SSI within 180 days following mastectomy with or without reconstruction was 8.1% (1,520 of 18,696). In total, 49% of SSIs were identified within 30 days post-mastectomy, 24.5% were identified 31-60 days post-mastectomy, 10.5% were identified 61-90 days post-mastectomy, and 15.7% were identified 91-180 days post-mastectomy. The incidences of SSI were 5.0% (395 of 7,860) after mastectomy only, 10.3% (848 of 8,217) after mastectomy plus implant, 10.7% (207 of 1,942) after mastectomy plus flap, and 10.3% (70 of 677) after mastectomy plus flap and implant (P<.001). The SSI risk was higher after bilateral compared with unilateral mastectomy with immediate reconstruction (11.4% vs 9.4%, P=.001) than without (6.1% vs 4.7%, P=.021) immediate reconstruction.
CONCLUSIONS: SSI incidence was twice that after mastectomy with immediate reconstruction than after mastectomy alone. Only 49% of SSIs were coded within 30 days after operation. Our results suggest that stratification by procedure type facilitates comparison of SSI rates after breast operations between facilities.

Entities:  

Mesh:

Year:  2015        PMID: 26036877      PMCID: PMC4693606          DOI: 10.1017/ice.2015.108

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  34 in total

1.  A comparison of ipsilateral pedicled TRAM flap with and without previous irradiation.

Authors:  Sean G Bristol; Peter A Lennox; Patricia A Clugston
Journal:  Ann Plast Surg       Date:  2006-06       Impact factor: 1.539

2.  Evolution of the pedicled TRAM flap: a prospective study of 500 consecutive cases by a single surgeon in Asian patients.

Authors:  Eun Key Kim; Jin Sup Eom; Sei Hyun Ahn; Byung Ho Son; Taik Jong Lee
Journal:  Ann Plast Surg       Date:  2009-10       Impact factor: 1.539

3.  Use of prophylactic postoperative antibiotics during surgical drain presence following mastectomy.

Authors:  Brandy L Edwards; George J Stukenborg; David R Brenin; Anneke T Schroen
Journal:  Ann Surg Oncol       Date:  2014-08-20       Impact factor: 5.344

4.  Declining incidence of contralateral breast cancer in the United States from 1975 to 2006.

Authors:  Hazel B Nichols; Amy Berrington de González; James V Lacey; Philip S Rosenberg; William F Anderson
Journal:  J Clin Oncol       Date:  2011-03-14       Impact factor: 44.544

5.  Late results of skin-sparing mastectomy followed by immediate breast reconstruction.

Authors:  T J Meretoja; S Rasia; K A J von Smitten; S L Asko-Seljavaara; H O M Kuokkanen; T A Jahkola
Journal:  Br J Surg       Date:  2007-10       Impact factor: 6.939

6.  Statewide costs of health care-associated infections: estimates for acute care hospitals in North Carolina.

Authors:  Deverick J Anderson; Deborah G Pyatt; David J Weber; William A Rutala
Journal:  Am J Infect Control       Date:  2013-02-27       Impact factor: 2.918

7.  Acellular dermis-assisted prosthetic breast reconstruction versus complete submuscular coverage: a head-to-head comparison of outcomes.

Authors:  Hani Sbitany; Sven N Sandeen; Ashley N Amalfi; Mark S Davenport; Howard N Langstein
Journal:  Plast Reconstr Surg       Date:  2009-12       Impact factor: 4.730

8.  Hospital-associated costs due to surgical site infection after breast surgery.

Authors:  Margaret A Olsen; Sorawuth Chu-Ongsakul; Keith E Brandt; Jill R Dietz; Jennie Mayfield; Victoria J Fraser
Journal:  Arch Surg       Date:  2008-01

9.  Outcomes and patient satisfaction following breast reconstruction with bilateral pedicled TRAM flaps in 105 consecutive patients.

Authors:  Yoon S Chun; Indranil Sinha; Arthur Turko; Stuart Lipsitz; Julian J Pribaz
Journal:  Plast Reconstr Surg       Date:  2010-01       Impact factor: 4.730

10.  Can additional information be obtained from claims data to support surgical site infection diagnosis codes?

Authors:  David K Warren; Katelin B Nickel; Anna E Wallace; Daniel Mines; Victoria J Fraser; Margaret A Olsen
Journal:  Infect Control Hosp Epidemiol       Date:  2014-10       Impact factor: 3.254

View more
  19 in total

1.  Surveillance and Prevention of Surgical Site Infections in Breast Oncologic Surgery with Immediate Reconstruction.

Authors:  Margaret A Olsen; Katelin B Nickel; Ida K Fox
Journal:  Curr Treat Options Infect Dis       Date:  2017-05-11

2.  THE EPIDEMIOLOGY AND OUTCOMES OF BREAST CANCER SURGERY.

Authors:  Victoria J Fraser; Katelin B Nickel; Ida K Fox; Julie A Margenthaler; Margaret A Olsen
Journal:  Trans Am Clin Climatol Assoc       Date:  2016

3.  The Evolution of Breast Implant Infections: Serratia marcescens Is an Emerging Pathogen in Implant-Based Breast Reconstruction.

Authors:  Jane L Gui; Kant Y Lin
Journal:  Plast Surg (Oakv)       Date:  2019-02-21       Impact factor: 0.947

Review 4.  The Efficacy of Prophylactic Negative Pressure Wound Therapy for Closed Incisions in Breast Surgery: A Systematic Review and Meta-Analysis.

Authors:  David Cagney; Lydia Simmons; Donal Peter O'Leary; Mark Corrigan; Louise Kelly; M J O'Sullivan; Aaron Liew; Henry Paul Redmond
Journal:  World J Surg       Date:  2020-05       Impact factor: 3.352

5.  Immediate Implant-Based Breast Reconstruction with Acellular Dermal Matrix: A Comparison of Sterile and Aseptic AlloDerm in 2039 Consecutive Cases.

Authors:  Rajiv P Parikh; Gabriella M Brown; Ketan Sharma; Yan Yan; Terence M Myckatyn
Journal:  Plast Reconstr Surg       Date:  2018-12       Impact factor: 4.730

6.  Validation of ICD-9-CM Diagnosis Codes for Surgical Site Infection and Noninfectious Wound Complications After Mastectomy.

Authors:  Margaret A Olsen; Kelly E Ball; Katelin B Nickel; Anna E Wallace; Victoria J Fraser
Journal:  Infect Control Hosp Epidemiol       Date:  2016-12-15       Impact factor: 3.254

7.  Prevalence and Predictors of Postdischarge Antibiotic Use Following Mastectomy.

Authors:  Margaret A Olsen; Katelin B Nickel; Victoria J Fraser; Anna E Wallace; David K Warren
Journal:  Infect Control Hosp Epidemiol       Date:  2017-07-03       Impact factor: 3.254

8.  Comparison of Wound Complications After Immediate, Delayed, and Secondary Breast Reconstruction Procedures.

Authors:  Margaret A Olsen; Katelin B Nickel; Ida K Fox; Julie A Margenthaler; Anna E Wallace; Victoria J Fraser
Journal:  JAMA Surg       Date:  2017-09-20       Impact factor: 14.766

9.  Development of a Risk Prediction Model to Individualize Risk Factors for Surgical Site Infection After Mastectomy.

Authors:  Margaret A Olsen; Katelin B Nickel; Julie A Margenthaler; Ida K Fox; Kelly E Ball; Daniel Mines; Anna E Wallace; Graham A Colditz; Victoria J Fraser
Journal:  Ann Surg Oncol       Date:  2016-01-28       Impact factor: 5.344

10.  Effect of Noninfectious Wound Complications after Mastectomy on Subsequent Surgical Procedures and Early Implant Loss.

Authors:  Katelin B Nickel; Ida K Fox; Julie A Margenthaler; Anna E Wallace; Victoria J Fraser; Margaret A Olsen
Journal:  J Am Coll Surg       Date:  2016-02-05       Impact factor: 6.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.